[{"address1": "301 Binney Street", "address2": "Suite 402", "city": "Cambridge", "state": "MA", "zip": "02142", "country": "United States", "phone": "617 401 9975", "website": "https://www.synlogictx.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.", "fullTimeEmployees": 6, "companyOfficers": [{"maxAge": 1, "name": "Mr. Antoine  Awad", "age": 43, "title": "Principal Executive Officer", "yearBorn": 1980, "fiscalYear": 2023, "totalPay": 580326, "exercisedValue": 0, "unexercisedValue": 47094}, {"maxAge": 1, "name": "Dr. Timothy K. Lu M.D., Ph.D.", "age": 42, "title": "Co-Founder & Member of Scientific Advisory Board", "yearBorn": 1981, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James J. Collins Ph.D.", "age": 57, "title": "Co-Founder & Member of Scientific Advisory Board", "yearBorn": 1966, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Mary Beth Dooley", "age": 42, "title": "VP, Head of Finance and Principal Financial Officer & Principal Accounting Officer", "yearBorn": 1981, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brendan St. Amant", "title": "General Counsel & Corporate Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ajay  Munshi", "title": "Vice President of Corporate Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Adam J. Thomas", "title": "Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Caroline B. Kurtz Ph.D.", "title": "Chief Development Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Molly  Harper", "age": 46, "title": "Chief Business Officer", "yearBorn": 1977, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Neal  Sondheimer M.D., Ph.D.", "title": "VP & Head of Clinical", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.58, "open": 1.68, "dayLow": 1.57, "dayHigh": 1.68, "regularMarketPreviousClose": 1.58, "regularMarketOpen": 1.68, "regularMarketDayLow": 1.57, "regularMarketDayHigh": 1.68, "beta": 1.035, "forwardPE": -12.307693, "volume": 8330, "regularMarketVolume": 8330, "averageVolume": 36793, "averageVolume10days": 39540, "averageDailyVolume10Day": 39540, "marketCap": 18731200, "fiftyTwoWeekLow": 0.234, "fiftyTwoWeekHigh": 5.708, "priceToSalesTrailing12Months": 5.844368, "fiftyDayAverage": 1.7845, "twoHundredDayAverage": 2.056245, "currency": "USD", "enterpriseValue": 884217, "floatShares": 3619691, "sharesOutstanding": 11707000, "sharesShort": 24246, "sharesShortPriorMonth": 38580, "sharesShortPreviousMonthDate": 1711584000, "dateShortInterest": 1714435200, "sharesPercentSharesOut": 0.0021, "heldPercentInsiders": 0.15568, "heldPercentInstitutions": 0.60675, "shortRatio": 0.79, "shortPercentOfFloat": 0.0061000003, "bookValue": 1.146, "priceToBook": 1.3961606, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -73224000, "trailingEps": -8.02, "forwardEps": -0.13, "lastSplitFactor": "1:7", "lastSplitDate": 1503878400, "enterpriseToRevenue": 0.276, "enterpriseToEbitda": -0.019, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "SYBX", "underlyingSymbol": "SYBX", "shortName": "Synlogic, Inc.", "longName": "Synlogic, Inc.", "firstTradeDateEpochUtc": 1443619800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "30bbb3c7-ab0a-33b2-91a8-e57d2c890111", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.6, "targetHighPrice": 1.0, "targetLowPrice": 1.0, "targetMeanPrice": 1.0, "targetMedianPrice": 1.0, "recommendationMean": 3.0, "recommendationKey": "hold", "numberOfAnalystOpinions": 1, "totalCash": 32311000, "totalCashPerShare": 2.76, "ebitda": -47745000, "totalDebt": 14464000, "quickRatio": 2.953, "currentRatio": 3.194, "totalRevenue": 3205000, "debtToEquity": 108.548, "revenuePerShare": 0.382, "returnOnAssets": -0.47755, "returnOnEquity": -1.78515, "freeCashflow": -20154250, "operatingCashflow": -45545000, "revenueGrowth": -0.954, "grossMargins": 1.0, "operatingMargins": -1319.5, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-26"}]